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The formation of immune complexes (IC), due to the inter-
action of foreign substances with specific antibodies, is a
physiological process which constitutes an essential part of
man's normal immune defense mechanisms. This reaction is
generally followed by one or more secondary reactions, all of
which enable the body to neutralize and clear microorganisms
and non-self molecules (in the form of IC after antibody
binding) that have penetrated the various body barriers. Inac-
tivation and elimination of these "invaders" prevents their
deposition (localization) where they might multiply (in the case
of microorganisms) or induce specific damage (toxins or
enzymes). IC formation followed by these secondary reactions
(such as complement fixation) enhances MPS clearance mech-
anisms and prevents interaction with specific sites in the body
that could be damaged by deposition. This entire dynamic
process must be very efficient under normal circumstances,
because although we are constantly exposed to and challenged
by foreign pathogens, IC do not normally accumulate in blood
or organs.
However, there are circumstances under which potentially
pathogenic IC might form in the circulation and not be cleared
properly. Factors that could influence this phenomenon and the
manifestations of specific disease activity include the nature
and quantity of the antigen and the antibody response (that is,
IC characteristics), and the state of the systems involved in IC
clearance (complement, complement receptors, and receptors
on fixed cells of the MPS for both complement components and
the Fc region of immunoglobulins). There is obviously an
infinite variety of potential antigens (from whole organisms to
small peptides), and the antibody response can vary with
respect to class, subclass, affinity, etc. Thus, it should be clear
that IC characteristics will be quite variable and that analysis of
one IC system may not be applicable to other systems as well.
Several specific examples illustrate this point. A patient with
a monoclonal antibody against flavin became "yellow" because
of the ubiquitous accumulation of flavin [1]. Apparently the
antibody/flavin IC was cleared from the circulation at a much
slower rate than flavin alone; the small IC (one antibody per IC)
was too small to be cleared by the MPS, yet clearance of the
flavin was apparently blocked by the antibody. In rare patients
autoantibodies to amylase, prostatic acid phosphatase or crea-
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tine kinase can block the clearance of these enzymes by a
similar mechanism [2—4]. Finally, it is well known that nephritic
factor is an autoantibody that stabilizes the alternative pathway
C3 convertase in the circulation, thus inducing C3 depletion [5].
These examples illustrate one end of the spectrum in which the
antigen is caused to circulate for excessive periodsof time due
to complexation with specific antibody and formation of a small
IC; it is likely that the half-life for clearance of such IC
approaches that of the immunoglobulin involved, which is
roughly three weeks for IgG.
At the opposite end of the spectrum are patients with mixed
essential cryoglobulinemia. Large quantities of precipitating IC
(containing IgG and/or 1gM, and specific antigens) deposit at
sites throughout the body, including the glomeruli [6]. These IC
can fix complement and cause local damage at their sites of
deposition [7, 8].
It is likely that many IC that form in the circulation will have
properties intermediate between these two extremes. The bal-
ance between rapid and safe clearance versus tissue localization
will then be influenced by faciors that have been described in
part in experimental studies but have yet to be well defined in
humans. These include the potential affinity of antibody Or
antigen for specific tissue (such as, DNA for GBM [9]), and the
hemodynamic and inflammatory status of the individual. For
example, it is possible to facilitate the deposition of 1gM and C3
in vessel walls of rheumatoid arthritis patients with an intrader-
mal injection of histamine [101. In addition, the specific immu-
nochemical properties of the IC, and in particular their potential
to interact with Fc receptors and to fix complement, and react
with complement receptors will fundamentally influence their
ultimate fate and rate of clearance from the circulation.
These considerations suggest that although various assays
have been developed to measure IC in the blood, the fraction
found in venous blood at any one time is unlikely to provide a
good account of the complex processes of the handling of IC in
the circulation (the sea level provides no information on the
height of the waves!). We suggest below that there are a number
of reasons why, with few exceptions, there has been no general
agreement between IC measurements and disease activity.
IC concentrations may be different between arterial and
venous blood, particularly if the IC deposit in capillaries or
small veins [11]. The IC detected in the circulation might be
irrelevant, because the pathogenic species could have already
deposited. IC formation and clearance can not be a steady state
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process; even during chronic serum sickness the concentrations
of antigen, antibody, and IC vary continuously [12—14]. Thus,
damaging IC could form and deposit in a brief period of time.
For example, patients with essential mixed cryoglobulinemia
have sudden episodes of purpura over their legs and arms, and
then their vasculitis subsides despite the presence of measur-
able IC. In selected patients with SLE, Swank et al [15] have
shown that rapid decreases in the titer of anti-dsDNA antibod-
ies presaged disease activity; they recognized that this effect
could have been due to the release of a bolus of DNA into the
circulation, followed by the rapid deposition of the newly
formed IC. It is also not possible to discriminate between
non-harmful and damaging IC through the use of available
assays. For example, patients with rheumatoid arthritis often
have very high plasma levels of material that binds Cl q, but few
have signs of vasculitis, and nephritis is exceptional [16].
Finally, some IC will circulate bound to erythrocytes, and can
not be detected in most IC assays, unless specific steps are
taken to release them into the plasma [17].
Thus, as it is unlikely that IC measurements will provide
useful information, we suggest that it is more important to
define the circumstances that will lead to the abnormal clear-
ance of IC, or to identify specific IC that may be harmful. The
first approach has demonstrated that defects in the MPS can be
associated with disease activity and provides one important
mechanism for the inefficient clearance of circulating IC [18].
In this review we will discuss another aspect of the physio-
logical elimination of IC from the circulation. Recent evidence
suggests that complement and its receptor on erythrocytes
provide an efficient system for processing and transporting large
IC [19]. This system has been studied in vitro and in vivo in
various animal models [19—22], and preliminary data have been
obtained in vivo in humans [23]. The interaction of IC with
complement can drastically alter such biophysical properties as
the ability of the IC to come out of solution (that is, complement
mediated inhibition of immune precipitation, lIP) [24, 25]. In
addition, the covalent attachment of C3 fragments to IC allows
them to bind to various cells containing C3 receptors, in
particular the C3b receptors on erythrocytes (complement-
mediated immune adherence, IA) [26, 27]. The altered proper-
ties of the IC due to interaction with the complement-erythro-
cyte system can significantly affect their mechanism of
clearance from the circulation. The fundamental hypothesis,
which has been expressed independently in varying forms by
several different investigators, is that complement and erythro-
cytes inhibit the formation or deposition of pathogenic IC in
tissues, thus preventing or significantly reducing the potential
consequences of immune-complex mediated diseases. A num-
ber of recent reviews have dealt with different aspects of the
clinical and experimental data in support of this hypothesis [28—
32]. In order to avoid redundancy we will focus the present
discussion on how the molecular immunochemistry of the
IC-complement-erythrocyte interaction may affect the fate of
circulating IC.
Complement mediated inhibition of immune precipitation (lIP)
In 1941, while studying immune precipitation, Heidelberger
noted that 'particulation was greatly delayed in the tubes
containing active complement and the precipitates remained
more finely divided and settled less readily in the other tubes"
[33]. This observation was repeated years later by other inves-
tigators who confirmed that complement interfered with immu-
noprecipitation [34]. More recently the details of this reaction in
certain defined antibody-antigen systems have been examined
[24]. When radiolabelled BSA and rabbit anti-BSA antibodies
were mixed in the presence of human serum, no precipitation
took place. When complement activation was blocked by
trettting the serum with EDTA or by heating it for 30 minutes at
56°C, then inhibition of precipitation was abrogated.
A number of other important findings have been reported
since these experiments.
(1) The soluble IC formed by lip are very large (>19 S, that
is, more than 1000 kD), and contain various complement
fragments (Cl, C4, C3) in addition to both antibody and
antigen. Incorporation of these complement components into
the IC lattice appears to modify its solubility. Covalent binding
of C3 fragments is particularly important in maintaining IC
solubility. This binding reaction involves an internal thioester
bond in C3. Upon complement activation by immune com-
plexes, this bond is broken and nascent C3b is generated which
is capable of reacting with nucleophilic amino or hydroxyl
groups (on the antibody, antigen, or water in the most general
case) to form amide and ester bonds, respectively [35, 36].
Hong et al [371 used the ovalbumin/anti-ovalbumin system to
investigate the substrate specificity of this reaction in more
detail. They found that C3b formed amide bonds with the heavy
chain of IgG because this bond was not destroyed by hydrox-
ylamine treatment (which is known to break ester bond link-
ages).
The precise mechanism by which complement, and in partic-
ular C3b, modifies IC solubility is not understood. One possi-
bility, suggested by Lachmann and Walport [38], is that incor-
poration of C3b decreases the valence of IgG from two to one,
thus decreasing the ability of the IC to form large cross-linked
structures. Alternatively, it is also possible that C3b in some
manner (sterically?) interferes with Fe-Fe interactions that are
believed to be responsible for the rapid aggregation of IC [39,
40]. Whether it is an antibody-antigen bond or an antibody-
antibody interaction which is weakened, in either case C3b
must decrease cross linking of the IC, and this would tend to
maintain them in solution. It should be emphasized that the size
of the IC per se may not be directly related to its solubility
because incorporation of C3b usually increases the size of IC
formed at antibody excess [41]. However, such IC (tetanus
toxoid (TT)/anti-TT antibody), although increased in size in the
presence of complement, remain soluble, presumably because
their degree of cross linking is either decreased or unchanged
after complement opsonization. On the other hand, the IC are
precipitated if they are treated with agents such as IgM-RF or
Clq that are known to induce cross linking (especially at lower
temperature) because of their multivalency for IgG [42, 43].
(2) Details of the sequence by which complement components
participate in lip are now available, a) Macromolecular Cl
delays immune aggregation in a dose-dependent manner, both
in its activated and non-activated form [44]. This effect is most
evident in the first few minutes of the reaction when the IC first
are formed, but is lost after prolonged incubation. Presumably
the macromolecular Cl complex interfered with the Fe-Fe
interactions that occur quite rapidly and are responsible for the
initial immune aggregation [39, 40]. However, it had little effect
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Fig. 1. Immune precipitation in human serum deficient in C4 (D).
Normal serum (A) inhibits precipitation, which is restored upon block-
ade of complement function with EDTA (A). The partial precipitation
of IC in C4 def serum is abolished upon C4 repletion (U) (adapted from
the Journal of Clinical Investigation [25]).
on the slower redistribution of the antibody-antigen bonds
which lead to formation of precipitating large lattice structures.
This mechanism of macromolecular Cl is confirmed by the
observation that Cl inhibitor reverses its action (and induces
precipitation) by disassembling activated Cl from the complex
and leaving only Clq on the IC. Clq enhances immune precip-
itation, as already noted (42]. This effect can also be replicated
by the addition of EDTA, which dissociates the Cl complex by
chelating calcium. These experiments indicate that under phys-
iological conditions the direct solubilizing effect of Cl will be
short lived, due to the action of Cl inhibitor and IC rearrange-
ment.
b) A more important role for Cl on the IC is that after it is
activated, it can cleave C4 and C2. This reaction allows the
capture of a small fraction of C4b by the IC, and formation of
the classical pathway C3 convertase (C4bC2a). It is the next
step in the reaction, C3 activation and capture of C3b by the IC,
that renders the IC soluble [25]. Formation of the C3 convertase
is a vital step in lIP; sera deficient in either C4 or C2 are not
capable of sustaining liP. However, only 1% of the normal C4
concentration is sufficient to restore TIP in C4 deficient serum
[25] (Fig. 1); this strongly supports the idea that C4 simply has
a catalytic function in facilitating C3 binding, but does not play
a direct molecular role in inhibiting immune precipitation.
c) Mter C3b is deposited on the IC, amplification of comple-
ment activation by the alternative pathway can occur. This
reaction may be enhanced because it appears that C3b bound to
IgG is at a "protected site" that is not easily degraded by factor
I [45]. This alternative pathway activation also reduced the size
of the IC that were maintained in solution by the classical
pathway of complement activation [46]. The explanation for
this effect remains speculative, but it is possible that deposition
of C3b at other acceptor sites on the IgG (perhaps containing
hydroxyl groups) further disrupted the immune complex lattice
by interfering with specific antibody-antigen bonds.
(3) Late components of complement have no measurable
effect on liP, which is not surprising as there is no evidence for
direct interaction of these proteins with the IC lattice [25, 47].
Furthermore, cellular receptors for complement (such as, CR1
or DAF) do not influence lIP, as the reaction gives quite similar
results in citrated blood compared to citrated plasma, and in
serum supplemented to a normal hematocrit compared to serum
alone (Schifferli, unpublished).
(4) The isotype of the antibody in the IC is of major impor-
tance in the lIP reaction. For example, although IC containing
IgG or 1gM are maintained in solution by complement, IC
containing IgA precipitate [48]. The nature of the antigen and
the input antibody/antigen stoichiometry also influence the
efficiency of the lIP reaction. In addition, the complement
consuming capacity of the IC does not necessarily correlate
with its ability to bind C3b and remain in solution. For example,
IgG-monoclonal 1gM RF complexes consume complement rap-
idly but appear to capture little C3b [49]. In fact, the molecular
details of the capture of C3b by 1gM in a variety of IC (and the
susceptibility of the covalent bonds to factor I mediated degra-
dation), are important questions which must be addressed [50].
Finally, it is possible for proteins in plasma to interfere with
complement-mediated reactions. 1gM-rheumatoid factor can
precipitate IC and thus interfere with lIP [51]. There is also
some evidence suggesting that "inhibitors" of complement
function in some SLE plasmas can diminish lIP [52].
Immune adherence
Nelson first demonstrated in 1953 that large complement
opsonized IC (whole microorganisms containing specific anti-
bodies) were able to bind to human erythrocytes [26]. This
reaction, termed immune adherence (IA), was later demon-
strated to occur both in vitro and in vivo with a variety of
defined soluble IC [19, 41, 53—55]. The results of intense activity
in this field over the last nine years have defined the role of
three variables in this binding reaction: the nature of the
complement receptor on the erythrocyte (CR1), the comple-
ment components required for binding, and the importance of
the biophysical chemistry of the IC in the reaction.
1) CR1, the complement receptor for C3b, is an intrinsic
membrane glycoprotein found on several different cell types. It
has a single polypeptide chain of molecular weight (reducing
conditions) of about 160 kD to 250 kD (4 alleles differing in size)
[56—59]. The polymorphism in the molecular weight of CR1 is
due to the presence of a varying number of extra copies of a
long homologous repeat unit of 450 amino acids [60]. CR1 binds
to the C3c region of C3b and C3bi, and therefore cannot bind
C3dg, the end product of the physiological inactivation of C3.
CR1 can directly participate in the inactivation of C3b
through its cofactor activity for Factor I [55, 61—64]. That is, the
binding of substrates containing C3b to cells containing CR1
facilitates the factor I mediated degradation of the fragments to
C3bi and then to C3dg, although some evidence suggests CR1
may not participate in the second degradative step (to C3dg)
under physiological conditions [65]. In any event, this sequence
of steps would infer that it should be possible for a C3b
opsonized IC to bind to a cell containing CR1, be released due
to degradation of the C3b to C3bi and C3dg [66], and then if the
40
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IC were capable of continuing to activate complement and
capture "fresh" C3b, rebind to the cell. In fact, this sequence of
reactions has been demonstrated for certain IC [551. One
interesting question which has not been answered concerns the
site(s) on IgG that capture C3b. Eventually it will be important
to know if there is a finite number (ito 2?) of "privileged" sites
that specifically capture C3b, and that once the C3b at the
site(s) has been degraded to C3dg, whether these particular IgG
can no longer participate in C3b capture and facilitate erythro-
cyte binding. Finally, CR1 also binds c4b, but with lower
affinity than it binds C3b [58, 67].
The various cells that contain CR! include erythrocytes,
polymorphonuclear leukocytes, monocytes, B lymphocytes,
follicular dendritic cells, and glomerular epithelial cells. The
number and function of CR1 molecules on erythrocytes and
polymorphonuclear leukocytes has been investigated in some
detail; however, less is known concerning CR1 on these other
cells, and its function on fixed tissue macrophages remains
speculative. The number of CR1 molecules on normal erythro-
cytes is only about 600, and leukocytes can have between 5000
and 50000 CR!, depending upon how these latter cells are
treated during their isolation [68, 69]. However, because of the
high concentration of erythrocytes in the circulation, approxi-
mately 90% of the total circulating CR1 is found on these cells
[701. The number of CR! per erythrocyte can vary among
healthy individuals (between about 200 and 1200), and this
characteristic is at least partially inherited [30, 7!]. However,
an acquired drop in this number has been observed in certain
diseases (SLE, AIDS, RA, etc.) [71—78], and although the
mechanism for this effect is still under active investigation, it is
believed that this decrease is a consequence of disease activity
and may be related to the presence or processing of comple-
ment-fixing IC in the circulation.
The affinity of monomeric C3b for CR! is quite low (about 106
liter/M), and although the C3b dimer has a slightly higher affinity
and can be used to quantitate CR!, it is unlikely that even the
dimer can bind to CR! under physiologic conditions (if it were
to be formed) [79, 80]. These observations, and the results of
analyses of the requirements for binding of defined comple-
ment-fixing dsDNA/anti-dsDNA IC to human erythrocytes,
indicate that efficient attachment of these IC to human eryth-
rocytes must be a multivalent reaction [54, 81].
At saturation no more than 100 dsDNA/anti-dsDNA IC bind
per erythrocyte (recall that each erythrocyte has about 600
receptors), and each of these IC can incorporate more than 100
C3b molecules. This would suggest that each IC binds to a small
"cluster" of CR1 via multiple C3b-CR1 contacts (between
about 4 and 10), and the fact that the association constant for
this interaction is so high (about 1011 iiter/M) is quite consistent
with this idea [23, 8 1—83]. This binding is also sufficiently high to
occur under physiologic conditions, and such binding has been
observed in vivo in both the non-primate model (where platelets
apparently have a similar C3b receptor) [84] and in several in
vivo primate models as well [4!, 50, 83, 85, 86]. Binding of other
complement-fixing IC to human and other primate erythrocytes
is also well documented, and it is reasonable to believe that a
similar mechanism for multivalent binding occurs for these IC
systems as well [29]. The difference in affinity for CR1 of
monomeric C3b versus the opsonized IC would suggest that any
free C3b generated in the circulation during complement acti-
vation would not effectively compete with the IC for CR1 sites
on the erythrocytes. A similar requirement for multivalent
binding is also believed to enable Fc receptors to discriminate
between monomeric !gG and larger IC [87].
The hypothesis of multivalent binding would infer that the
distribution of CR1 on human erythrocytes containing bound IC
can not be random. A homogeneous distribution would pre-
clude such IC binding, simply because of the small size of the
IC compared to the mean distance between randomly distrib-
uted CR1 on the erythrocyte. Further evidence for this concept
is the study of Horgan and Taylor, on the temperature depen-
dence of binding of complement-opsonized dsDNA/anti-
dsDNA IC to human erythrocytes [82]. Their data was consis-
tent with a rate determining step involving formation or
rearrangement of CR1 clusters. Finally, the clustered distribu-
tion of CR1 has been visualized by immunofluorescent and
electron microscopy techniques that indicate the presence of
well-defined dots, where each may represent a cluster (about 20
to 30 dots per erythrocyte) [88, Note Added in Proof].
(2) Several lines of evidence indicate that complement acti-
vation by the classical pathway is required to render IC immune
adherence positive. This has been demonstrated for different IC
(dsDNA/anti-DNA, TT/anti-TT, BSA/anti-BSA) in a variety of
procedures, including the use of purified complement proteins,
and complement deficient or depleted sera [41, 62, 89]. Binding
of C4b alone to the IC (in the absence of C3b) does not give
significant binding to erythrocytes, either because its affinity for
CR1 is low, or it is rapidly inactivated in plasma, or perhaps
because an insufficient number of C4b molecules are deposited
on the IC to allow for multivalent binding. As IC binding to
erythrocytes is partially dependent upon their size, it is possible
that the alternative pathway of complement activation might
even decrease the binding of IC to erythrocytes by decreasing
the size of the IC. Finally, the late components of complement
(CS to C9) appear to play no role in IA.
In whole blood the fraction of IC that are erythrocyte bound
will depend upon several dynamic processes [17, 23, 55, 62, 82,
901. These include the rates at which the IC can form, fix
complement and bind C3b, bind to the erythrocytes, and the
rate at which the C3b on the IC (either in the plasma or
erythrocyte bound) is degraded to C3dg, which would either
preclude binding or induce release, respectively. The concen-
tration and activity of factor I, the plasma enzyme responsible
for C3b inactivation, might also determine the release reaction
and the dynamics of exchange between erythrocytes and
plasma.
(3) The characteristics of the IC that engage in these comple-
ment-mediated reactions have been studied in several model
systems with varying degrees of physiologic relevance. Among
the IC investigated are: BSA/rabbit anti-BSA (IgG), TT/human
anti-TT (IgG), human IgG/human 1gM RF, DNA/human anti-
DNA (IgG and 1gM), DNP (dinitrophenyl)-BSA/mouse mono-
clonal anti-DNP (IgG and IgA), HBSAg (hepatitis B surface
antigen)/human anti-HBSAg antibody, and human IgG/rabbit
anti-human IgG (IgG) [19—21, 41,49,54,55,91]. This limited list
demonstrates that considerable attention has been paid to the
influence of particular IC properties on the IA reaction. How-
ever, in all systems analyzed the two most important charac-
teristics were the efficiency of complement activation and the
final size of the IC. These two parameters in turn would appear
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to reflect one fundamental property that must be considered in
IA. That is, the number of C3b captured per IC and the three
dimensional distribution of C3b on the IC ultimately determines
the potential of the IC to bind to erythrocytes [921.
Thus, the larger the IC, the more efficiently it should capture
C3b and bind to erythrocytes. IC size will be influenced by the
nature of the antibody and antigen, and their absolute and
relative concentrations in solution. For example, IC formed
with HBSAg (3000 kD) are larger and give more binding to
human erythrocytes than those formed with TT (150 kD)
(Paccaud and Schifferli, unpublished). IC formed with the
former antigen can bind more IgG, and probably capture more
C3b. It is important to recognize that most antigens should also
be capable of capturing C3b, and this would also increase net IC
binding.
The dsDNA/human anti-dsDNA antibody (IgG) IC system,
which is obviously of physiological relevance because of its role
in SLE pathogenesis [32, 93, 94], is particularly attractive for
quantitative analyses of complement-mediated binding to hu-
man erythrocytes [54, 811. These IC do not precipitate, because
as first demonstrated by Aarden, Degroot and Lakmaker, they
do not show significant cross linking [95]; rather, the IgG
antibodies tend to bind monogamously and with high avidity
and stability to individual dsDNA molecules. Also, based on
the dsDNA structure, and recent experiments [92] it is unlikely
that the dsDNA antigen captures any C3b, and this can simplify
analyses of binding. Thus, at antibody excess, the properties of
these IC are determined by the molecular weight of the dsDNA.
As the dsDNA increases in size, more antibodies can bind, and
the number of IgG capable of fixing complement and capturing
C3b, per IC, increases. The importance of dsDNA molecular
weight in this system was first demonstrated by Lennek et al
[54] who studied the IA of IC formed between IgG anti-dsDNA
antibodies and dsDNA fragments varying in size from 200 base
pairs (about 140 kD) to 1500 base pairs (about 1000 kD) (Fig. 2).
IA of the IC formed with the various dsDNA fragments
increased almost linearly with dsDNA size from 0% binding to
almost 80% binding. Much larger dsDNA substrates (9000 base
pairs) did not significantly improve binding. The lower level of
binding for the smaller dsDNA fragments (in the 20 to 60%
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binding range) probably represents IC which have marginal
levels of C3b. That is, very large immune-complexed dsDNA
molecules have so many bound IgG that they easily capture
enough C3b to insure formation of the multivalent binding site
to the cluster of CR1 on the erythrocyte. Smaller immune-
complexed dsDNA molecules will capture lower numbers of
C3b, and presumably only a fraction of these IC will have a
sufficient number of C3b in proper geometric "register" to
engage the CR1 binding cluster.
We suggest that the varying levels of IA reactivity reported
for other IC-containing protein antigens are also influenced by
the quantity and distribution of C3b they capture. In addition,
these other IC are more labile and often are prepared at either
antigen or antibody excess to avoid precipitation. Thus, the
phenomenon of antigen/antibody redistribution in such IC could
lead to a decrease in IA reactivity. It is likely that similar
considerations would explain the observation that the factor I
mediated release of erythrocyte bound IC containing protein
antigens is generally faster than the comparable release reaction
for IC containing dsDNA [17].
Finally, it is important to recognize that other factors, such as
antibody class, can be more important than IC size in the IA
reaction. Waxman Ct al [211 demonstrated that at equal size IC
formed with monoclonal IgA anti-DNP antibodies bound less
efficiently to primate erythrocytes than those formed with
monoclonal IgG antibodies. This result is quite reasonable as
IgA is less efficient than IgG in fixing complement via the
classical pathway [96].
Complement receptor transport of IC in the circulation
When large complement-fixing IC are injected into animals,
they rapidly bind to cells bearing receptors for C3b [19, 22, 86,
97]. These cells are erythrocytes in humans and other primates,
but are platelets in the rodents that have been investigated:
rabbits, guinea pigs, and mice. Although the C3b receptor on
the human erythrocyte has been well characterized, the isola-
tion and detailed characterization of the comparable receptor
on the erythrocytes of non-human primates and on rodent
platelets is currently an area of active research [84]. For the
sake of discussion (and absent any data to the contrary), we will
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Fig. 2. Formation of DNA -antiDNA IC using
DNA fragments of increasing size mixed with
3 different SLE sera containing high titers of
IgG and anti-dsDNA antibodies. The
formation of IC is attested by precipitation of
- the radiolabelled DNA in the Fan assay. The
z binding of the IC to normal erythrocytes
Q (RBC-CF assay) is directly dependent on the
size of the DNA fragment used, that is, to the
size of the IC. The points off the lines were
e obtained for sera containing 1gM anti-dsDNA
antibodies. Binding to erythrocytes was
obtained with more concentrated scm than
was used in the Fan assay (adapted from the
Journal of Immunology [54]). Symbols are:
(•) Mu/3, (•) Wr/5, (A) Wb/5;FARR, (0)
Mu/50, (EJ) Wr/lOO, (A) Wb/20.Number of base pairs
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refer to all these receptors as having the same function as
human CR!.
Studies in animal models
In 1975 Miller et al injected poorly soluble IC into mice and
demonstrated that these complexes bound readily to circulating
platelets [98]. This binding was absent in old hypocomplemen-
temic NZB/W mice (which display an IC associated disease
much like SLE) and could be partially restored by pretreating
the IC with mouse complement (fresh serum) before injection.
However, these pre-opsonized IC still showed less in vivo
binding to the platelets of old NZB/W mice compared to that
observed in young NZB/W mice. The authors speculated that
the failure to restore as much binding in the old mice might have
been due to appropriate receptors being "unavailable" for
binding. In view of the numerous latter reports concerning
decreased CR1 on erythrocytes and neutrophils in SLE [71—75,
77, 78, 99], this finding in the mouse model system seems quite
reasonable, and might be an important subject of further
investigation in this and other mouse models for SLE. Finally,
the rate of clearance of the IC (with or without prior comple-
ment opsonization) was approximately the same in both young
and old mice, but no data on organ localization was reported.
Hebert et al have defined the biological role of the erythro-
cyte IC transport system in a number of non-human primate
models [19—22]. This work was recently discussed in detail in a
review in this journal [29], and so only the major points that
have emerged from these studies will be mentioned here.
Preformed BSAIanti-BSA IC injected into the aorta of baboons
bind in seconds to minutes to erythrocytes, and remain stably
bound in the circulation until the erythrocytes pass through the
liver or spleen, where the IC are "unloaded" to fixed cells
(macrophages, presumably), but the erythrocytes appear to
recirculate immediately without any delay. These results sug-
gest that the IC are rapidly released from the erythrocytes
(having only C3b receptors) and bind to macrophages and
possibly other fixed cells that presumably have C3b, C3b1,
C3dg, and Fc receptors. The exact mechanism by which the IC
are released from the erythrocytes is a matter currently under
investigation, and could involve the actions of Factor I and
perhaps other cell based proteases, as well as specific macro-
phage receptors.
Hebert and co-workers also demonstrated that either com-
plement depletion, through use of cobra venom factor (deple-
tion of C3), or complement inhibition, through use of heparin,
blocked IC binding to the erythrocytes [20]. Under these
conditions removal of plasma associated IC by the liver and
spleen was still quite efficient and similar to the rate of removal
in the untreated animals. However, there was a simultaneous
disappearance of IC outside these organs, in particular in the
lungs and kidneys. This implies that IC free in the blood stream
(not erythrocyte bound) may be more easily trapped in the
microvasculature. These experiments might be criticized be-
cause of the possibility of other non-specific effects due to the
complement depletion in the animals. However, in an additional
series of studies Hebert et al manipulated the immunochemistry
of the IC instead, and obtained further evidence for such
"trapping" of non-erythrocyte bound IC. They injected IgA
and IgG anti-DNP IC of similar size simultaneously. In agree-
ment with earlier studies, the IC containing IgG bound to
erythrocytes and were cleared almost entirely by the liver and
spleen [21]. IC containing IgA showed less binding to erythro-
cytes, and a measurable fraction (presumably from the plasma
associated IC) was recovered in the lungs, and in the kidneys,
where the complexes were found trapped in the glomeruli.
These experiments provide clear evidence for the existence
of an IC transport system in the circulation of primates. The
erythrocytes are not stimulated by the IC and appear to simply
behave as carriers. The situation in the rodent model, where
platelets bind IC in the circulation, may be quite different. For
example, during serum sickness in rabbits, large IC will form at
the site of antigen injection, fix complement, and bind to
platelets. In vitro data indicates this reaction will activate
platelets, as they aggregate rapidly and form an insoluble clump
(Paccaud and Schifferli, unpublished). These observations may
explain the role of platelets in inducing or perpetuating vascular
injury in the many rodent IC models studied to date; in view of
the "change" to erythrocytes in primates from platelets in
non-primates [84], it is doubtful the rodent serum sickness
model will be directly relevant for human pathology.
DNA/anti-DNA IC have been used by Taylor and colleagues
to define the characteristics of the IC that engage or evade the
transport system in both non-primates and primates [50, 85, 86].
In general, larger IC which bound more C3b gave greater in
vivo binding to platelets and erythrocytes, respectively, in
agreement with previous in vitro studies. This led the authors to
suggest that dsDNA/anti-dsDNA IC of intermediate size, or
ssDNA/anti-DNA IC, both of which are capable of activating
complement but show only partial or low binding to erythro-
cytes, might be more pathogenic since they would have time to
circulate freely through capillaries where they could be trapped.
All studies described to this point were conducted with pre-
formed IC. It is important to know whether IC that actually
form in the circulation behave similarly to the preformed IC
Edberg, Kujala and Taylor [85] have demonstrated that the
injection of dsDNA into the circulation of either rabbits or
monkeys "primed" with anti-dsDNA antibodies does lead to
rapid formation of complement-fixing IC that bind to platelets
and erythrocytes respectively, in the two animals (Fig. 3).
Thus, the full sequence of events does occur in vivo for an IC
system that has been repeatedly implicated in the pathogenesis
of SLE.
Studies in humans
The clearance of preformed large, soluble complement-fixing
TT/anti-TT IC from the circulation of humans has recently been
investigated by Schifferli and co-workers [23, Note Added in
Proofi. The results obtained were similar to those previously
reported for IC in baboons, in that both erythrocyte CR1 and
complement played a role in the processing and clearance of
these IC; however, as previously demonstrated in the baboon
experiments, the erythrocytes transporting the IC were not
taken up by the MPS, nor delayed in their transit through it.
After i.v, injection, the TF/anti-TT IC evidenced maximum
binding to the erythrocytes quite rapidly (about 1 mm). How-
ever, the fraction of IC bound varied between individuals,
where those with low CR! numbers per erythrocyte had less
binding than those with high CR1 levels. This was an unex-
pected finding, because there was ample complement in the
circulation to opsonize the IC, and there was a large excess of
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Fig. 3. Clearance of IC formed in vivo in a rabbit (A) and a rhesus monkey (B). The IC were formed by the successive injection of
SLE-gammaglobulin (containing anti-dsDNA antibodies) and 1251-dsDNA. The disappearance of IC (TCA insoluble counts) (0) occurs within
minutes, and a large fraction of them binds to cells bearing C3b receptors (•), platelets and erythrocytes respectively (adapted from the Journal
of Immunology [851).
CR! compared to the IC injected. This effect may be explained
in part by recognizing that each IC may bind to only a single
erythrocyte, and that the number of C3b, per IC, must vary as
well. Thus, even though overall CR1 may be at excess, per
erythrocyte it could be limiting, with respect to formation of
sufficiently large CR! binding clusters capable of engaging even
the IC with a lower number of incorporated C3b. Finally, a
similar result was obtained for the in vitro binding of defined
dsDNA/anti-dsDNA IC to the CR! deficient erythrocytes of
SLE patients [74, 82].
Other factors expected to influence in vivo binding include
the inactivation of C3b by factor I, which will cause release of
the IC, as mentioned previously. Thus, at any time after i.v.
injection, there is an equilibrium between binding and release
reactions, and CR1 number per erythrocyte may strongly
influence this system. This was confirmed in two other experi-
ments with the TT/anti-TT system. First, when IC already
bound to autologous erythrocytes were injected, a significant
fraction of the bound IC were released, and the amount of
release was largest in individuals with the lowest number of
CR1 per erythrocyte. Second, in vitro experiments indicate the
TT/anti-TT IC can exchange between erythrocytes, and binding
to erythrocytes with the highest number of CR1 is favored [83].
The clearance rate of the TT/anti-TT IC could be explained
by a simple compartmental model. IC disappearance in most
normal individuals was monoexponential and rapid (about 11%
cleared per minute), which is similar to the findings for dsDNAI
anti-dsDNA IC clearance in baboons [22]. However, in the
three SLE patients studied a significant fraction of the IC, about
20%, disappeared almost immediately after injection. It is likely
that this fraction was rapidly trapped in the microvasculature
before reaching the MPS. IC binding in vivo was lower to
erythrocytes of the SLE patients, and this reduced binding
probably allowed a significant fraction of the IC to be trapped in
various tissues. This result is quite comparable to the previ-
ously discussed enhanced tissue deposition seen by Hebert and
Cosio [29] in experiments in which the erythrocyte clearance
mechanism was compromised by either blocking complement
activation or using IC containing IgA.
These observations may help explain the physiological or
pathological elimination of IC in humans. If large complement-
fixing IC are injected in the circulation, they should be effi-
ciently cleared by the MPS. However, during this process IC
may be trapped in the kidneys, lungs, skin, etc., and such
trapping can result in local damage due to the phlogistic
properties of the IC. Prevention of significant trapping will
depend upon many factors: First, IC bound to erythrocytes will
remain in the central stream of the vessels where the erythro-
cytes circulate (Fig. 4). Second, local conditions such as
increased vascular permeability (due to release of anaphylato-
xins as a consequence of IC mediated complement activation)
[100] could allow plasma associated IC to deposit more effi-
ciently. Third, the dynamic equilibrium between erythrocyte
associated and free IC, which will depend upon the nature of
the IC, the complement status of the individual (including factor
I activity), and the immunochemical properties of the IC, will
obviously play an important role in this complex process.
Immunopathology of the transport system
Various factors can cause the erythrocyte transport system to
fail, including excess IC formation (SLE, cryoglobulinemia,
bacterial endocarditis) [101], inherited complement deficiency
or depletion due to disease activity, and CR! deficiency, which
apparently can be either inherited or acquired as a consequence
of IC-associated disease activity. Under these circumstances IC
may rapidly form large insoluble aggregates that do not bind to
erythrocytes but instead deposit in certain tissues and cause
local damage. We illustrate this hypothesis with two examples.
It is evident from the previous discussion that IC containing
IgA do not enter the erythrocyte-complement transport system,
and this could have immunopathologica! implications. IgA
nephropathy and Henoch SchOnlein purpura are characterized
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Fig. 4. The transport of JC by erythrocytes in
small blood vessels.
by glomerular IgA deposits, increased synthesis of IgA and the
presence of circulating IC containing IgA [1021. Although the
IgA found in the messangium could be specific for a structural
antigen, it is more probable that the large poorly soluble IC
containing IgA are trapped in the mesangium, as has been found
for other large IC, Ample experimental evidence supports this
mechanism [1031, and the deposition of IgA IC in other organs
and the skin and GI tract would confirm it. As previously noted,
IgA does not activate the classical complement pathway, and
Hebert's experiments demonstrate defective binding of IgA IC
to erythrocytes, and their deposition in glomeruli. Although
secretory IgA acts as a first line of defense in the secretions in
protecting against microorganisms, the role of plasma IgA in
immunity is not as clear [96]. It would seem that IgA is not the
appropriate class of Ig for blood clearance of soluble antigens.
Type II cryoglobulins containing monoclonal 1gM RF provide
an interesting second example of IC that escape efficient
clearance. Although these IC activate complement in vitro,
when the IgG purified from these IC was injected back into the
patients, the resulting IC that formed (the IgG was complexed
by the monoclonal 1gM RF), were not cleared rapidly [1041.
Evidently the 1gM RF covered the Fc regions of the IgG, and
apparently there is no specific receptor for immune complexed
1gM. The patients all had low complement levels, and the IC
were not able to bind sufficient C3b to bind to erythrocytes [49].
Thus, there were multiple reasons for the persistence of these
IC in the circulation.
Although we have emphasized the potential importance of
large IC circulating for brief periods of time, the evidence in
support of this concept is indirect. Relevant examples include
the detection of IC-like material on the surface of erythrocytes
in some SLE patients [17], and the finding of immune deposits
in tissues. It is possible that in glomeruli, focal subendothelial
and mesangial immune aggregates could be due to the accretion
of circulating antigens, antibodies, or rheumatoid factors, de-
pending upon specific circumstances [7, 17, 103]. The finely
detailed progress in the blood stream of a pathogenic IC will be
difficult to follow, because it appears that in most cases the time
during which this IC will remain circulating will be extremely
short.
It is evident that defects in the complement-erythrocyte
transport system as reviewed here represent only one aspect of
IC mediated disease. This system acts as a physiological
safeguard that may normally help process and eliminate IC that
form during the body's immunologic surveillance and defense
activities. As such, it would not normally be expected to be the
"limiting factor" which, upon breakdown, leads to disease.
SLE, the prototype IC mediated disease, is often characterized
by either complement or CR1 deficiency, as well as defective
MPS activity. If under these conditions there was either a
chronic or acute challenge to the body by circulating IC with
some of the defined immunochemical properties we have dis-
cussed, then the symptoms of IC mediated disease would
certainly be anticipated. Which combination of these factors
will be sufficient to cause similar problems in other IC mediated
diseases is a matter for continued investigation.
Summary
Complement participates in the elimination of IC in many
circumstances. When antigen/antibody IC first form in the
circulation, complement inhibits their aggregation because the
covalent binding of C3b to the IC modifies their biophysical
properties and they remain soluble. Such opsonized (C3b
coated) IC attach to cells bearing C3b receptors (CR1) in the
circulation, in particular to erythrocytes, since in humans 85 to
90% of CR! in the blood is located on these cells. This immune
adherence binding reaction appears to be a physiological sys-
tem that allows IC to be transported through the circulation to
the fixed macrophages of the MPS where they are safely
eliminated. The deposition of circulating complement-fixing IC
in various organs such as the kidney may be considered as a
failure of this transport system. This is apparent in complement
deficient and depleted states, and also for non-complement-
fixing IC (IgA IC). The formation of insoluble IC (by definition
immune deposits found in human pathology are insoluble)
produces complement activation and inflammation at the site of
the immune aggregate.
Acknowledgments
J.A.S. is the recipient of a Max Cloëtta Career Development Award.
R.P.T. is grateful to the N.I.H. (AR 24083] for continued support.
Blood vessel wall
ICc
a— (Cc
Ic + c —0 ICc —
A9/Qc3000
• Plasma . _______
I.,.,., • .1
Immune complex transport by the jetstream
Schifferli and Taylor: Circulating immune complexes 1001
Reprint requests to Jflrg A. Schifferli, Clinique Medicate, Dépar-
tement de Médecine, Hôpital Cantonal Universitaire, 1211 Geneva 4,
Switzerland.
Appendix I. Abbreviations
bovine serum albumin
dinitrophenyl
double stranded deoxyribonucleic acid
glomerular basement membrane
hepatitis B surface antigen
immune adherence
immune complex(es)
inhibition of immune precipitation
mononuclear phagocytic system
rheumatoid factor
tetanus toxoid
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